source
- Merck and Daiichi withdraw FDA accelerated approval filing for B7-H3 ADC in small cell lung cancerMerck and Daiichi Sankyo announced they have withdrawn their joint FDA accelerated approval filing for a B7-H3 antibody-drug conjugate intended for a subset of small cell lung cancer patients. The…
- Operational talent, not just science, will drive next biopharma breakthroughsThe piece points out that while breakthrough science, founders and venture funding are typical markers of progress, the real test is moving a promising therapy through GMP production, quality syste…